Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 4/20 | 0.39 |
| ▸ | BRD1 | O95696 | 3/20 | 0.39 |
| ▸ | BRPF3 | Q9ULD4 | 3/20 | 0.39 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | AR | P10275 | 3/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | CDC7 | O00311 | 8/20 | 0.36 |
| ▸ | CDK2 | P24941 | 4/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.36 |
| ▸ | ESRRA | P11474 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4580723 | 0.84 | ROCK1 (0.43) | HTR6CDC7 | |
| SCHEMBL14291379 | 0.80 | NR4A1 (0.40) | — | |
| SCHEMBL4581465 | 0.79 | ICMT (0.41) | BRPF1BRD1BRPF3BRD9HTR6 | |
| SCHEMBL4580931 | 0.77 | ENPP3 (0.45) | ARCDC7CDK2MAP3K14 | |
| SCHEMBL27400816 | 0.74 | ENPP3 (0.48) | BRPF1BRD1BRPF3BRD9HTR6 | |
| SCHEMBL20604726 | 0.73 | FFAR4 (0.44) | HTR6ARCDC7CDK2 | |
| SCHEMBL29687043 | 0.70 | AR (0.58) | ARSLC6A4ESRRA | |
| SCHEMBL524339 | 0.70 | AR (0.58) | ARSLC6A4ESRRA | |
| SCHEMBL13535540 | 0.68 | PIP4K2A (0.40) | ARCDC7 | |
| SCHEMBL524184 | 0.67 | AR (0.51) | ARSLC6A4LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | claimed |
| WO-2008024978-A2 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | claimed |
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | MKI67, CCNB1, RB1 | BRPF1 115/4885BRD1 51/4885BRPF3 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.